Black Diamond Therapeutics (BDTX) Other Non-Current Liabilities (2018 - 2019)
Black Diamond Therapeutics' (BDTX) quarterly Other Non-Current Liabilities came in at $16000.0 in Q4 2019, down 99.6% on a YoY basis from $4.0 million in Q4 2018, and down 99.6% quarter-over-quarter from $4.0 million in Q4 2018.
Powered by 
Analysis
Black Diamond Therapeutics (BDTX) Other Non-Current Liabilities (2018 - 2019) Analysis & Trends
Black Diamond Therapeutics (BDTX) has reported Other Non-Current Liabilities for 2 consecutive years, with $16000.0 the latest figure, recorded in Q4 2019.
- For the quarter ending Q4 2019, Other Non-Current Liabilities fell 99.6% year-over-year to $16000.0; the trailing twelve-month figure through Dec 2019 stood at $16000.0 (down 99.6% YoY), and the FY2019 full-year result was $16000.0, down 99.6% from the prior year.
- Other Non-Current Liabilities declined to $16000.0 in Q4 2019 per BDTX's latest filing, from $4.0 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $4.0 million in Q4 2018 and bottomed at $16000.0 in Q4 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Black Diamond Therapeutics | 111.58 Mn | 1.07 Mn | - |